Free Trial

Indivior (LON:INDV) Trading 8.1% Higher

Indivior logo with Medical background

Indivior PLC (LON:INDV - Get Free Report) traded up 8.1% during trading on Thursday . The company traded as high as GBX 848 ($10.86) and last traded at GBX 843 ($10.80). 1,729,744 shares traded hands during mid-day trading, an increase of 223% from the average session volume of 534,858 shares. The stock had previously closed at GBX 780 ($9.99).

Analysts Set New Price Targets

Separately, Deutsche Bank Aktiengesellschaft cut their price target on Indivior from GBX 2,350 ($30.10) to GBX 1,500 ($19.21) and set a "buy" rating for the company in a research note on Tuesday.

Read Our Latest Report on INDV

Indivior Trading Up 8.1 %

The firm has a fifty day simple moving average of GBX 1,310.67 and a two-hundred day simple moving average of GBX 1,415.90. The stock has a market cap of £1.14 billion, a PE ratio of 28,100.00, a PEG ratio of -5.57 and a beta of 0.06. The company has a current ratio of 0.93, a quick ratio of 1.52 and a debt-to-equity ratio of 2,790.00.

About Indivior

(Get Free Report)

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose.

Featured Stories

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Should you invest $1,000 in Indivior right now?

Before you consider Indivior, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Indivior wasn't on the list.

While Indivior currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Top 3 Bargain Stocks to Buy at Their 52-Week Lows
Top Small-Cap Picks as Russell 2000 Nears All-Time High
Top Stock Picks Amid Tech Market Meltdown

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines